Effects of ethyl lauroyl arginine nasal spray on COVID-19

A randomized, double-blind, multicenter study to evaluate the efficacy and safety of ethyl lauroyl arginine hydrochloride (ELAH) formulation administered as a nasal spray to reduce viral load in the nasal area in subjects with coronavirus disease 2019 (COVID-19)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN17834262

Enrollment

Registered

2022-04-26

Start date

2021-08-02

Completion date

Unknown

Last updated

2022-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) Infections and Infestations

Interventions

Subjects were enrolled after obtaining written informed consent and were screened for eligibility for the study based on inclusion and exclusion criteria. For confirmation of COVID-19, subjects underw

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Signed informed consent 2. Confirmed for Covid-19 infection by RT-PCR tests

Exclusion criteria

Exclusion criteria: 1. Allergy to ELAH 2. Females who were breast feeding or lactating 3. History of severe respiratory infections 4. Have received period Covid treatment 5. Participated in any interventional drug trial in previous 30 days

Design outcomes

Primary

Measure	Time frame
1. Viral load measured using RT-PCR test post treatment (day 6) 2. Number of Covid-19 free subjects measured using RT-PCR test post treatment (day 6)	—

Secondary

Measure	Time frame
Safety and tolerability of Covixyl-V LAEH nasal spray were assessed by evaluating AEs, serious adverse events (SAEs), vital signs, treatment discontinuation due to AEs, and nasal and physical examinations using patient records at the end of the study	—

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026